+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SUNPHARMA

Sun Pharmaceutical Industries Share Price

₹1,930.00 -2 (-0.1%)
52W high on Jul 31, 2026

14 Aug, 2026 3:58 PM (IST)

Sun Pharmaceutical Industries live price: ₹1,930.00. It opened at ₹1,932 vs previous close ₹1,932; intraday high/low: ₹1,937/₹1,915. The 50 & 200 DMA stand at ₹1,910.40/₹1,806.30.

Sun Pharmaceutical Industries Performance

  • Today's Low
  • ₹1,915
  • Today's High
  • ₹1,937
  • 52 Week Low
  • ₹1,548
  • 52 Week High
  • ₹2,047
  • Open Price₹1,932
  • Previous Close₹1,932
  • Volume918,112
  • 50 DMA₹1,910.40
  • 100 DMA₹1,861.10
  • 200 DMA₹1,806.30

Sun Pharmaceutical Industries Chart

Investment Returns

  • Over 1 Month -0.65%
  • Over 3 Month + 3.59%
  • Over 6 Month + 13.7%
  • Over 1 Year + 17.58%

Smart Investing Starts Here Start SIP with Sun Pharmaceutical Industries for Steady Growth!

Invest Now

Sun Pharmaceutical Industries Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 38.3
  • PEG Ratio
  • 2.3
  • Market Cap Cr
  • 463,072
  • P/B Ratio
  • 5.5
  • Average True Range
  • 30.3
  • EPS
  • 50.4
  • Dividend Yield
  • 0.8
  • MACD Signal
  • 6.9
  • RSI
  • 47.09
  • MFI
  • 38.88

Latest Stock News Updates

Delhi HC directs Sun Pharma to take permission before launching semaglutide

Delhi High Court ordered Sun Pharma to seek judicial approval before launching semaglutide tablets, following a patent infringement suit by Novo Nordisk. The order requires Sun Pharma to return to court once it secures a manufacturing licence.

Sun Pharma voluntarily recalls 11 eyedrops from domestic market, experts seek details

Public health experts are calling for greater transparency involving specifics on why the eyedrops were recalled, besides seeking regulatory intervention and advisory for those who may have already used the drops

Sun Pharma posts higher quarterly profit on strong demand

Consolidated net profit in Q1 rises to 2,895 crore ($303.54 million) from 2,279 crore a year earlier

Sun Pharmaceutical Industries Financials

Sun Pharmaceutical Industries Technicals

EMA & SMA

Current Price
₹1,930.00
-2 (-0.1%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹1,944.40
  • 50 Day
  • ₹1,910.40
  • 100 Day
  • ₹1,861.10
  • 200 Day
  • ₹1,806.30

Resistance and Support

1927.23 Pivot Speed
  • R3 1,962.10
  • R2 1,949.50
  • R1 1,939.80
  • S1 1,917.50
  • S2 1,904.90
  • S3 1,895.20

Sun Pharmaceutical Industries Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-31 Quarterly Results
2026-05-22 Audited Results & Final Dividend
2026-01-31 Quarterly Results & Interim Dividend
2025-11-05 Quarterly Results
2025-07-31 Quarterly Results
Date Purpose Remarks
2026-07-07 FINAL Rs.5.00 per share(500%)Final Dividend
2026-02-05 INTERIM Rs.11.00 per share(1100%)Interim Dividend
2025-07-07 FINAL Rs.5.50 per share(550%)Final Dividend
2025-02-06 INTERIM Rs.10.50 per share(1050%)Interim Dividend
2024-07-12 FINAL Rs.5.00 per share(500%)Final Dividend
View Sun Pharmaceutical Industries Dividend History Arrow
Date Purpose Remarks
2010-11-26 Split Stock split from Rs. 5/- to Re. 1/-.
2003-01-21 Split Face value changed from Rs. 10/- to Rs. 5/-

Sun Pharmaceutical Industries F&O

Sun Pharmaceutical Industries Shareholding Pattern

54.48%
14.54%
12.84%
9.33%
8.81%

About Sun Pharmaceutical Industries

Active Pharma Ingredients (APIs) & variety of branded & generic formulations are produced, developed, & marketed by Sun Pharmaceuticals Industries Ltd. With global presence in trading & other ancillary activities, the corporation & its subsidiaries operate multiple manufacturing facilities across the globe, catering to the global market. It is India's biggest pharmaceutical corporation. Product Offerings: company manufactures a wide range of specialty & generic medications to address a variety of acute & chronic medical conditions. Generics, branded generics, specialist, hard-to-make technology-intensive pharmaceuticals, antiretrovirals, APIs, & intermediates are all part of its product line. It provides medications in every possible dose form, including liquids, tablets, sprays, ointments, creams, injectables, & capsules.

Indian Branded Generics: Largest Pharma business in India with 8.3% market share; Approximately 32% of revenues in FY23. Prescriptions with 12 classes of prescribers rank it first as well. In India, Sun Pharma leads the market in the chronic category. In India's top 300 pharmaceutical brands, it has 32 brands. Among other specialties, gastroenterology makes up 12%, neuropsychiatry 16%, & cardiology 18%.

US Business (~31% of revenues): This company ranks second in the US dermatology industry by prescriptions & joined the US pharma market in 1997. In terms of US generics, it ranks tenth. There were 616 ANDAs & 67 NDAs filed as of Q1FY24, & 519 ANDAs & 54 NDAs that had been authorized for a variety of therapies.

13 NDAs & 97 ANDAs are awaiting USFDA clearance. OTC, generics, & specialty markets are areas where corporations are well-represented. Liquids, creams, ointments, gels, sprays, injectables, tablets, capsules, drug-device combinations, & other products are sold by the company.
 

View More
  • NSE Symbol
  • SUNPHARMA
  • BSE Symbol
  • 524715
  • ISIN
  • INE044A01036

Similar Stocks to Sun Pharmaceutical Industries

Sun Pharmaceutical Industries FAQs

Sun Pharmaceutical Industries share price is ₹1,930 As on 16 August, 2026 | 03:32

The Market Cap of Sun Pharmaceutical Industries is ₹463071.7 Cr As on 16 August, 2026 | 03:32

The P/E ratio of Sun Pharmaceutical Industries is 38.3 As on 16 August, 2026 | 03:32

The PB ratio of Sun Pharmaceutical Industries is 5.5 As on 16 August, 2026 | 03:32

The 52 week High & Low of Sun Pharmaceutical Industries is ₹2046.9/₹1548 respectively As on 16 August, 2026 | 03:32

Sun Pharmaceutical Industries (Sun Pharma) has an operating revenue of INR 36,704.43 Cr. on a trailing 12-month basis. Annual revenue growth of 3% is not great, Pre-tax margin of 8% is okay. Institutional holding has gone up in the last reported quarter is a positive sign. Analyst Recommendation on Sun Pharmaceutical Industries (Sun Pharma): HOLD

Dilip Shanghvi is the Managing Director of Sun Pharmaceutical Industries (Sun Pharma).

The ROE of Sun Pharmaceutical Industries (Sun Pharma) is 6% which is fair but needs improvement.

Sun Pharmaceutical Industries (Sun Pharma) has a reasonable debt to equity of 2%, which signals a healthy balance sheet.

The PE ratio of Sun Pharmaceutical Industries (Sun Pharma) is 81.5.

Metrics for analyzing sun pharma share price include: P/E Ratio, ROE, Profit Growth, as it Shows historical earnings growth.

To buy Sun Pharmaceuticals Industries Ltd shares, open a 5paisa account, fund it, search for Sun Pharmaceuticals Industries Ltd , place buy order, & confirm.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23